danuglipron + cyclosporine

**Danuglipron + cyclosporine** refers to the *co-administration* of **danuglipron**, an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, and **cyclosporine**, an immunosuppressant. This combination is under study to assess potential pharmacokinetic interactions and safety when both drugs are administered together. Danuglipron acts by stimulating the GLP-1 receptor, enhancing glucose-dependent insulin release, reducing appetite, and promoting weight loss. Cyclosporine suppresses immune activation primarily via calcineurin inhibition, blocking T-cell signaling. The combination is not a marketed therapy but has been investigated in healthy volunteers to evaluate if cyclosporine affects the pharmacokinetics or safety profile of danuglipron[1][2]. As of 2025, danuglipron’s development for chronic weight management and diabetes was discontinued by Pfizer[2][3].